Startup profile · funding coverage
Ventus Therapeutics
Structure-based drug discovery biotech using computational chemistry for small molecules.
Stage
growth
Status
private
Coverage
full
Why Ventus Therapeutics is interesting
ReSOLVE platform targets 'undruggable' proteins — $140M Series C from SoftBank and RA Capital with a16z on cap table.
Key facts
- Series C (Feb 2022): $140M co-led by SoftBank Vision Fund 2 and RA Capital; a16z participated (Ventus press)
- Co-investors not in VCT directory: SoftBank Vision Fund 2, RA Capital, GV, Versant Ventures
- VCT directory co-investors: none mapped (non-directory syndicates noted above); reviewed 2026-07-24
Investors in our directory
Funds linked from Ventus Therapeutics's profile — open a fund page for stage focus and related deal articles.
Industries
Healthtech Biotech & Life Sciences
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
Related funding articles
Venture Capital Tracker pieces that cover Ventus Therapeutics's financing or category context.
Last updated: 2026-07-24